ArticleEye (London, England)2025
Photoreceptor layer thinning is an early biomarker for type 2 diabetes: a cohort study in UK Biobank.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the association between photoreceptor outer segment (POS) thickness and the risk of T2D.
methodsThis prospective cohort study included 35,024 UK Biobank participants with high-quality optical coherence tomography (OCT) images, excluding individuals with neurological or ocular diseases. Cox proportional hazard models were used to analyse the association between baseline POS thickness and incident T2D. Risk model improvement was assessed using net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
resultsAmong 35,024 participants (mean age, 55.6 years; 54.0% women), 1187 (3.39%) developed T2D during a median follow-up of 13.18 years. A decrease of 5 μm in POS thickness was linked to a 10% higher risk of T2D (HR, 1.10; 95% CI, 1.02-1.18; P = 0.010). Participants in the lowest tertile of POS thickness had a 22% higher T2D risk compared to those in the highest tertile (HR, 1.22; 95% CI, 1.06-1.42; P = 0.007). Adding POS thickness to traditional risk models significantly improved predictive accuracy (NRI, 0.0356; P = 0.010; IDI, 0.0003; P = 0.010).
conclusionsPOS thinning detected by OCT is significantly associated with an increased risk of T2D and improves risk prediction when added to conventional models. These findings suggest that POS thickness may serve as a novel biomarker for early detection of T2D, supporting timely interventions to reduce risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.